Clinical trials: Depression Moderate
Hepatic Impairment
Pharmacokinetics of AGO178 in Participants With Liver Impairment
AGO178 was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).
- Trial name
- NCT01531309
- Testing
- AGO178
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Depressive Symptoms Mild to Moderate in Severity
Therapeutic Touch and Acupressure on Depressive Symptoms
Therapeutic touch intervention Participants in the therapeutic touch group received eight sessions over four weeks (two sessions per week), with each session lasting approximately 20 minutes.
- Trial name
- Postmenopausal (NCT07532512)
- Testing
- Therapeutic touch intervention, Acupressure intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Osmaniye Korkut Ata University
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Major Depressive Disorder (MDD)
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.
- Trial name
- NCT07101120
- Testing
- KH607 tablets
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Mild to Moderate Depression
Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.
The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation
- Trial name
- NCT02981225
- Testing
- Phytostandard® Rhodiola-Saffron
- Where
- France
- Volunteers
- 59 people
- Sponsor
- PiLeJe
Depression, Anxiety
Comparing Message-based Psychotherapy to Once-weekly, Video-based Psychotherapy for Moderate Depression and Anxiety
This study is concerned with evaluating an innovative care delivery platform that is becoming widely available but has not been adequately evaluated in a clinical trial.
- Trial name
- NCT05467787
- Testing
- Message-based psychotherapy (MBP), Video-chat Psychotherapy (VCP)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Talkspace
Depressive Disorder, Depressive Symptoms
Implementation of a Psychological Online Intervention for Low to Moderate Depression in Primary Health Care
Implementation of a psychological online intervention for low to moderate depression in primary care settings.
- Conditions
- Depressive Disorder, Depressive Symptoms, Depression
- Trial name
- NCT05294614
- Testing
- "Sonreír es diveritdo" - Smiling is fun
- Where
- Spain
- Volunteers
- 420 people
- Sponsor
- Universitat Jaume I
Dementia
The Effect of Digital Reminiscence Therapy on People With Mild and Moderate Dementia
In the post-epidemic era, it is necessary to develop support programs for families with dementia in empirical care. The reminiscence therapy was adopted by patients with mild and moderate dementia those intervention have had good…
- Trial name
- NCT05341271
- Testing
- Experimental: digital reminiscence group (DRG), Experimental: general reminiscence group (GRG)
- Where
- Taiwan
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- National Taipei University of Nursing and Health Sciences
Anxiety Disorder, Chronic Myeloproliferative Disorders
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
RATIONALE: Music therapy may be effective in relieving pain and emotional distress in patients who are undergoing cancer therapy.
- Conditions
- Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma
- Trial name
- NCT00014482
- Testing
- pain therapy, psychosocial assessment and care
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Depressive Symptoms Mild to Moderate in Severity
A Pilot Study of Synbiotics in Adults With Depressive Symptoms
This study aims to explore the efficacy and safety of a synbiotic formula (MQU10) in improving mood and well-being in adults with mild to moderate depressive symptoms.
- Trial name
- NCT06905223
- Testing
- MQU10
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- GenieBiome Limited
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Pregnancy, Postpartum
HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children
Regular exercise during pregnancy and postpartum leads to health benefits for mother and child. Inactivity during pregnancy and after delivery is now treated as risky behavior.
- Conditions
- Pregnancy, Postpartum, Childbirth, Health Status
- Trial name
- HIIT MAMA (NCT05009433)
- Testing
- High intensity interval training program for pregnant women, Moderate intensity continuous training program for pregnant women, Standard obstetric care with extended education on healthy lifestyle
- Where
- Poland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Gdansk University of Physical Education and Sport
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Major Depression Moderate, Major Depression Severe
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07748091
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Infant, Newborn, Hypoxia, Brain
Preemie Hypothermia for Neonatal Encephalopathy
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01793129
- Testing
- Hypothermia, Normothermic Control
- Where
- 18 sites in United States
- Volunteers
- 168 people
- Sponsor
- NICHD Neonatal Research Network
Depression
Brief Behavioral Activation Treatment for Depression With Inpatients
The purpose of the current study was to examine Brief Behavioral Activation Treatment for Depressions (BATD) effectiveness, credibility, and acceptability with moderate to severly depressed inpatients.
- Trial name
- NCT02712918
- Testing
- Brief Behavioral Activation Treatment for Depression, Standard Care
- Volunteers
- 23 people
- Sponsor
- Lovisenberg Diakonale Hospital
Depression
Evaluation of the Bounce Back Program
Lifetime prevalence rates of Major Depressive Disorder (MDD) in Canada are between 10-12% with approximately 1.5 million Canadians reporting depression in any given year.
- Trial name
- NCT01324648
- Testing
- Telephone-supported self-help and GP treatment as usual, Unsupported self-help and GP treatment as usual, General practitioner treatment as usual
- Where
- 3 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Mild to Moderate Depression
EMI Therapy for Depression in Hong Kong
To determine if a two-week ecological momentary intervention (two EMA + one EMI daily) as augmentation to treatment as usual would reduce depressive symptoms, rumination levels, and functioning in subjects with mild to moderate…
- Trial name
- NCT06430476
- Testing
- EMI, EMA
- Where
- Hong Kong
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Major Depressive Disorder
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with…
- Trial name
- NCT01312922
- Testing
- PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
- Where
- 31 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- PharmaNeuroBoost N.V.
Mild to Moderate Depressive Symptoms
Online Self-healing Program
Background. Almost two thirds of adolescents experience a mental disorder before the age of 25. Among mental disorders, depression is one of the most common among young people aged between 15 to 24, with a prevalence of 13.5% to…
- Trial name
- iCBT-A (NCT07374653)
- Testing
- Online Cognitive Behaviural Therapy, Online Relaxation
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- City University of Hong Kong